EU/3/06/404: Orphan designation for the treatment of Li Fraumeni Syndrome

Adenoviral vector containing human p53 gene

Table of contents


On 23 October 2006, orphan designation (EU/3/06/404) was granted by the European Commission to Gendux AB, Sweden, for adenoviral vector containing human p53 gene for the treatment of Li-Fraumeni syndrome.

The sponsorship was transferred to Gendux Molecular Limited, Ireland, in December 2007.

Key facts

Active substance
Adenoviral vector containing human p53 gene
Intended use
Treatment of Li Fraumeni Syndrome
Orphan designation status
EU designation number
Date of designation
Gendux Molecular Limited
70 Sir John Rogerson’s Quay
Dublin 2
Telephone: +353 1 849 1400
Telefax: +353 1 849 1401

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating